Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MC5R | P33032 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31265269 | 1.00 | CYP1A2 (0.62) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL130490 | 0.94 | CYP1A2 (0.61) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL12982444 | 0.92 | HDAC1 (0.59) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL4486003 | 0.92 | HDAC1 (0.59) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL133001 | 0.92 | HDAC1 (0.59) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL129285 | 0.92 | HDAC1 (0.59) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL9670577 | 0.91 | CYP1A2 (0.50) | CYP1A2SIGMAR1HDAC1HDAC8LTA4H | |
| SCHEMBL2307677 | 0.88 | CYP1A2 (0.54) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL2310861 | 0.88 | CYP1A2 (0.54) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 | |
| SCHEMBL79723 | 0.87 | CYP1A2 (0.56) | CYP1A2SIGMAR1HDAC1HDAC8CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2010-02-04 | — | — | US | claimed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | claimed |
| US-20240240226-A1 | FLUOROGENIC ASSAY FOR RAPID SCREENING OF BACTERIAL BETA-LACTAMASE ACTIVITY | UNIV LELAND STANFORD JUNIOR (US) | 2024-07-18 | — | — | US | disclosed |
| EP-3512602-B1 | INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF | HSF PHARMACEUTICALS (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2023-03-07 | — | — | US | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2021-07-22 | — | — | US | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3059235-B1 | TETRAZOLINONE DERIVATIVES AND THEIR USE FOR CONTROLLING PESTS | SUMITOMO CHEMICAL CO (JP) | 2020-10-28 | — | — | EP | disclosed |
| US-10675364-B2 | Rhodol fluorophores for near-infrared imaging | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-06-09 | — | — | US | disclosed |
| US-5422038-A | Ferroelectric liquid crystal material with sufficient spontaneous polarization, high speed response capability, wide temperature range | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-06-06 | — | — | US | disclosed |
| CN-1102640-A | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory and psychiatric disorders | SANKYO CO (JP) | 1995-05-17 | — | — | CN | disclosed |
| WO-1995012603-A1 | MATRIX METALLOPROTEASE INHIBITORS________________________________ | SYNTEX (U.S.A.) INC. (US) | 1995-05-11 | — | — | WO | disclosed |
| WO-1995004735-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-02-16 | — | — | WO | disclosed |
| EP-0416946-B1 | Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL CO (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-5134128-A | Immunosuppressive and antiproliferative activity for psoriasis and calcium homeostasis | ALLERGAN, INC. (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0416946-A2 | Optically active naphthalene derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-03-13 | — | — | EP | disclosed |
| EP-0372941-A2 | Anti-inflammatory 5-hydroxy-2-furanones | ALLERGAN, INC (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | CYP1A2 190/4885SIGMAR1 336/4885HDAC1 2548/4885 |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | CYP1A2 1700/4885SIGMAR1 4036/4885HDAC1 310/4885 |
| US-11597708-B2 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | CYP1A2 4682/4885SIGMAR1 4136/4885HDAC1 240/4885 |
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | CYP1A2 4682/4885SIGMAR1 4136/4885HDAC1 240/4885 |
| US-20240240226-A1 | FLUOROGENIC ASSAY FOR RAPID SCREENING OF BACTERIAL BETA-LACTAMASE ACTIVITY | CDA, CMBL, CTSF | CYP1A2 485/4885SIGMAR1 3002/4885HDAC1 4042/4885 |
| US-10675364-B2 | Rhodol fluorophores for near-infrared imaging | ALDH1A2, DNER, DBNL | CYP1A2 1045/4885SIGMAR1 3202/4885HDAC1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.